BRPI1015569B8 - compostos úteis para o tratamento de doenças degenerativas e inflamatórias - Google Patents

compostos úteis para o tratamento de doenças degenerativas e inflamatórias

Info

Publication number
BRPI1015569B8
BRPI1015569B8 BRPI1015569A BRPI1015569A BRPI1015569B8 BR PI1015569 B8 BRPI1015569 B8 BR PI1015569B8 BR PI1015569 A BRPI1015569 A BR PI1015569A BR PI1015569 A BRPI1015569 A BR PI1015569A BR PI1015569 B8 BRPI1015569 B8 BR PI1015569B8
Authority
BR
Brazil
Prior art keywords
diseases
treatment
inflammatory diseases
degenerative
compounds useful
Prior art date
Application number
BRPI1015569A
Other languages
English (en)
Inventor
Jeanne Marie Menet Christel
Kurt Smits Koen
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015569(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BRPI1015569A2 publication Critical patent/BRPI1015569A2/pt
Publication of BRPI1015569B1 publication Critical patent/BRPI1015569B1/pt
Publication of BRPI1015569B8 publication Critical patent/BRPI1015569B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos úteis para o tratamento de doenças degenerativas e inflamatórias. um novo composto capaz de inibir jak é descrito, este composto pode ser preparado como uma composição farmacêutica, e pode ser usa- do para prevenção e tratamento de uma variedade de condições em mamíferos incluindo seres humanos, incluindo a título de exemplo não limitante, conições inflamatórias, doenças autoimunes, doenças proliferativas, rejeiçãp de transplante, doenças envolvendo comprometimento de renovação de cartilagem, malforamções de cartilagem congênitas, e/ou doenças associadas , com hipersecreção de il6.
BRPI1015569A 2009-06-26 2010-06-25 compostos úteis para o tratamento de doenças degenerativas e inflamatórias BRPI1015569B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068809P 2009-06-26 2009-06-26
US61/220,688 2009-06-26
PCT/EP2010/059064 WO2010149769A1 (en) 2009-06-26 2010-06-25 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors

Publications (3)

Publication Number Publication Date
BRPI1015569A2 BRPI1015569A2 (pt) 2016-08-16
BRPI1015569B1 BRPI1015569B1 (pt) 2020-10-27
BRPI1015569B8 true BRPI1015569B8 (pt) 2021-05-25

Family

ID=42562363

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015569A BRPI1015569B8 (pt) 2009-06-26 2010-06-25 compostos úteis para o tratamento de doenças degenerativas e inflamatórias

Country Status (43)

Country Link
US (9) US8088764B2 (pt)
EP (2) EP3178819B1 (pt)
JP (2) JP5591925B2 (pt)
KR (3) KR101850716B1 (pt)
CN (2) CN102482273B (pt)
AR (1) AR077220A1 (pt)
AU (3) AU2010264633B2 (pt)
BR (1) BRPI1015569B8 (pt)
CA (1) CA2765985C (pt)
CL (1) CL2011003247A1 (pt)
CO (1) CO6491040A2 (pt)
CR (1) CR20120016A (pt)
CY (3) CY1119214T1 (pt)
DK (2) DK3178819T3 (pt)
DO (1) DOP2011000388A (pt)
EA (1) EA021637B1 (pt)
EC (1) ECSP12011626A (pt)
ES (2) ES2766573T3 (pt)
FR (1) FR21C1011I2 (pt)
GB (1) GB2483424B (pt)
HR (2) HRP20170826T1 (pt)
HU (3) HUE033154T2 (pt)
IL (1) IL216667A (pt)
LT (3) LT2445911T (pt)
MA (1) MA33448B1 (pt)
ME (1) ME02699B (pt)
MX (1) MX344951B (pt)
MY (1) MY156664A (pt)
NI (1) NI201100222A (pt)
NL (1) NL301096I2 (pt)
NO (1) NO2021013I1 (pt)
NZ (1) NZ596838A (pt)
PE (1) PE20121032A1 (pt)
PL (2) PL3178819T3 (pt)
PT (2) PT2445911T (pt)
RS (1) RS56035B1 (pt)
SG (2) SG177363A1 (pt)
SI (2) SI2445911T1 (pt)
SM (1) SMT201700265T1 (pt)
TW (1) TWI462920B (pt)
UA (1) UA107935C2 (pt)
WO (1) WO2010149769A1 (pt)
ZA (1) ZA201109386B (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CN105688214A (zh) * 2011-10-26 2016-06-22 艾米丽·A·斯坦 用于影响神经功能的药剂、方法和设备
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MX368511B (es) * 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
GB201302036D0 (en) * 2013-02-05 2013-03-20 Queen Mary & Westfield College Diagnosis
WO2015089153A1 (en) * 2013-12-11 2015-06-18 Cephalon, Inc. Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a] pyridine derivative
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
KR20170134750A (ko) 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
SMT202300328T1 (it) * 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
WO2017106568A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
CN108349974B (zh) * 2016-02-02 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
KR20180120273A (ko) * 2016-03-21 2018-11-05 크리스탈 파마테크 씨오., 엘티디. Jak 관련 질병 예방 또는 치료용 약물의 염산 결정성 형태 및 이의 제조 방법
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3492468B1 (en) 2016-07-26 2022-02-23 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
CN109715617B (zh) 2016-07-30 2022-04-19 百时美施贵宝公司 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
ES2902504T3 (es) 2016-09-09 2022-03-28 Bristol Myers Squibb Co Compuestos de indol sustituidos con piridilo
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
JP2019534304A (ja) 2016-11-10 2019-11-28 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性疾患の治療のための化合物及びその医薬組成物
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
FI3595667T3 (fi) 2017-03-14 2024-01-12 Galapagos Nv Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
EP3661926B1 (en) 2017-08-04 2022-02-23 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EA202091474A1 (ru) 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効なアミノインドール化合物
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
CN115029299B (zh) * 2018-11-07 2023-11-14 杭州瑞普晨创科技有限公司 JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
EP3939979A4 (en) 2019-03-14 2022-04-06 Shanghai Synergy Pharmaceutical Sciences Co., Ltd JAK-KINASE INHIBITOR, PROCESS FOR ITS PRODUCTION AND MEDICAL APPLICATIONS
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020201975A2 (en) 2019-03-30 2020-10-08 Unichem Laboratories Limited Novel process for the preparation of filgotinib and intermediates thereof
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
CN110204542B (zh) * 2019-05-23 2022-05-20 四川伊诺达博医药科技有限公司 一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) * 2019-06-03 2019-08-23 上海基科生物化学有限公司 一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
IT201900020240A1 (it) 2019-11-04 2021-05-04 Advitech Advisory And Tech Sa Procedimento per la preparazione di Filgotinib e intermedi di sintesi
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN110878097B (zh) * 2019-11-29 2021-11-02 杭州科巢生物科技有限公司 菲格替尼的制备方法
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2020428591B2 (en) 2020-02-13 2024-05-23 Zhuhai United Laboratories Co., Ltd. Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
WO2021168375A1 (en) 2020-02-20 2021-08-26 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2021164786A1 (zh) 2020-02-21 2021-08-26 珠海联邦制药股份有限公司 Jak抑制剂的晶型及其应用
US20240325393A1 (en) * 2020-08-17 2024-10-03 Vyne Therapeutics Inc. Tofacitinib-containing anhydrous elastomer-based gel formulations
WO2022072238A1 (en) * 2020-10-02 2022-04-07 University Of Massachusetts Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN115368389A (zh) * 2021-05-19 2022-11-22 奥锐特药业(天津)有限公司 一种Filgotinib中间体的制备方法
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
WO2023194842A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis
WO2026027676A1 (en) 2024-07-31 2026-02-05 Alfasigma S.P.A. Biomarkers for determining treatment of ulcerative colitis with filgotinib
WO2026027669A1 (en) 2024-07-31 2026-02-05 Alfasigma S.P.A. Biomarkers for determining treatment of ulcerative colitis with filgotinib

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ208996A (en) 1983-07-28 1989-08-29 American Cyanamid Co 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MX368511B (es) 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari

Also Published As

Publication number Publication date
FR21C1011I1 (pt) 2021-05-07
KR20120107919A (ko) 2012-10-04
CO6491040A2 (es) 2012-07-31
CR20120016A (es) 2012-02-09
GB2483424B (en) 2012-07-18
GB2483424A (en) 2012-03-07
US12042498B2 (en) 2024-07-23
SG177363A1 (en) 2012-02-28
DK2445911T3 (en) 2017-06-06
CA2765985A1 (en) 2010-12-29
TW201103936A (en) 2011-02-01
IL216667A (en) 2015-08-31
PL2445911T3 (pl) 2017-08-31
LT3178819T (lt) 2020-01-27
EP3178819B1 (en) 2019-12-04
HUS2100007I1 (hu) 2021-03-29
PT3178819T (pt) 2020-01-21
SI3178819T1 (sl) 2020-02-28
CY2021008I2 (el) 2021-06-25
PL3178819T3 (pl) 2020-04-30
FR21C1011I2 (fr) 2022-03-25
BRPI1015569A2 (pt) 2016-08-16
MX2011013450A (es) 2012-05-08
IL216667A0 (en) 2012-02-29
EA201270075A1 (ru) 2012-12-28
US20100331319A1 (en) 2010-12-30
HRP20200033T1 (hr) 2020-03-20
BRPI1015569B1 (pt) 2020-10-27
LT2445911T (lt) 2017-06-12
US8563545B2 (en) 2013-10-22
US8088764B2 (en) 2012-01-03
US8999979B2 (en) 2015-04-07
NL301096I1 (pt) 2021-03-24
AU2015218544B2 (en) 2017-04-27
PT2445911T (pt) 2017-06-12
PE20121032A1 (es) 2012-08-25
US20240325405A1 (en) 2024-10-03
CY1119214T1 (el) 2018-02-14
JP2014221825A (ja) 2014-11-27
MX344951B (es) 2017-01-12
TWI462920B (zh) 2014-12-01
US20200078365A1 (en) 2020-03-12
KR101916194B1 (ko) 2018-11-07
LTC2445911I2 (lt) 2022-09-26
KR20180041262A (ko) 2018-04-23
US20140100220A1 (en) 2014-04-10
US20160296530A1 (en) 2016-10-13
JP5591925B2 (ja) 2014-09-17
ECSP12011626A (es) 2012-02-29
SI2445911T1 (sl) 2017-07-31
US20150274722A1 (en) 2015-10-01
US9309244B2 (en) 2016-04-12
NL301096I2 (nl) 2021-04-12
MY156664A (en) 2016-03-15
DK3178819T3 (en) 2020-01-27
WO2010149769A1 (en) 2010-12-29
NI201100222A (es) 2012-07-27
AU2015218544A1 (en) 2015-09-17
KR101696669B1 (ko) 2017-01-16
DOP2011000388A (es) 2012-04-15
US9707237B2 (en) 2017-07-18
ME02699B (me) 2017-10-20
SG10201703497YA (en) 2017-06-29
HRP20170826T1 (hr) 2017-08-25
EP3178819A1 (en) 2017-06-14
RS56035B1 (sr) 2017-09-29
KR101850716B1 (ko) 2018-04-20
LTPA2021504I1 (lt) 2021-04-12
ZA201109386B (en) 2012-08-29
MA33448B1 (fr) 2012-07-03
HUE033154T2 (en) 2017-11-28
EP2445911A1 (en) 2012-05-02
AR077220A1 (es) 2011-08-10
US12558360B2 (en) 2026-02-24
CN102482273A (zh) 2012-05-30
CY2021008I1 (el) 2021-05-05
AU2017204744A1 (en) 2017-07-27
US20210369727A1 (en) 2021-12-02
AU2010264633A1 (en) 2011-12-22
CN104262337A (zh) 2015-01-07
NZ596838A (en) 2014-01-31
CN102482273B (zh) 2014-09-17
ES2766573T3 (es) 2020-06-12
US20180000831A1 (en) 2018-01-04
CY1122649T1 (el) 2021-03-12
HK1167403A1 (en) 2012-11-30
UA107935C2 (xx) 2015-03-10
GB201200457D0 (en) 2012-02-22
EA021637B1 (ru) 2015-07-30
AU2010264633B2 (en) 2015-06-04
ES2626908T3 (es) 2017-07-26
CL2011003247A1 (es) 2012-04-13
CA2765985C (en) 2017-06-06
EP2445911B1 (en) 2017-03-01
KR20170007534A (ko) 2017-01-18
JP2012530766A (ja) 2012-12-06
US10328081B2 (en) 2019-06-25
SMT201700265T1 (it) 2017-07-18
US20120142678A1 (en) 2012-06-07
US11000528B2 (en) 2021-05-11
HUE047478T2 (hu) 2020-04-28
NO2021013I1 (no) 2021-03-23

Similar Documents

Publication Publication Date Title
EA201270076A1 (ru) Новое соединение, применимое для лечения дегенеративных и воспалительных заболеваний
CR20120016A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
CL2011002818A1 (es) Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios.
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
HN2011001256A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CR20110092A (es) Nuevos compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias
CO6680683A2 (es) Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
BR112016016732A8 (pt) derivados de benzimidazol, seus usos, e composições farmacêuticas para tratamento de distúrbios inflamatórios
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
CL2011003050A1 (es) Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno.
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань
UA113722C2 (uk) Фармацевтична композиція
TH138979A (th) สารประกอบชนิดใหม่ที่มีประโยชน์สำหรับการรักษาโรคที่มีการเสื่อมสภาพและมีการอักเสบ

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)